CME in Minutes: Education in Primary Care

Please visit answersincme.com/860/101834101-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Simpa S. Salami, MD, MPH; and Neal D. Shore, MD, FACS. In this activity, experts in prostate cancer discuss new evidence for individualized, evidence-based treatment strategies in metastatic hormone-sensitive disease. Upon completion of this activity, participants should be better able to: Evaluate the clinical implications of the most recent data informing the standard of care treatment options for mHSPC; Integrate patient-, disease-, and therapy-related factors to develop individualized, evidence-based treatment strategies for mHSPC; and Design patient-centered care approaches that balance the benefit and risk of treatment to optimize outcomes in mHSPC.

Please visit answersincme.com/ZPW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by David R. Staskin, MD. In this activity, an expert in urology discusses strategies to diagnose and individualize treatment for overactive bladder (OAB) in patients with benign prostatic hyperplasia (BPH), including the role of beta-3 adrenergic agonists and guideline-based care. Upon completion of this activity, participants should be better able to: Identify strategies to diagnose overactive bladder (OAB) in patients with benign prostatic hyperplasia (BPH); Assess the evidence for beta-3 adrenergic agonists in the treatment of OAB among patients with BPH; and Outline approaches to tailor OAB treatment for individual patients with BPH.

Please visit answersincme.com/TNM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Richard Kim, MD. In this activity, an expert in oncology discusses when and how to sequence later-line and chemotherapy-free therapies in metastatic colorectal cancer (mCRC). Upon completion of this activity, participants should be better able to: Evaluate factors influencing a treatment switch from cytotoxic agents for patients with stable metastatic colorectal cancer (mCRC); Formulate practical approaches for transitioning from chemotherapy to tyrosine kinase inhibitor (TKI) treatment in later-line settings for patients with mCRC; and Describe strategies to prolong chemotherapy-free disease control with TKIs.

Please visit answersincme.com/KJW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aman Chauhan, MD and Rhonda K. Yantiss, MD. In this activity, experts in medical oncology and pathology discuss identification and treatment of extrapulmonary neuroendocrine carcinomas and extrapulmonary neuroendocrine tumors. Upon completion of this activity, participants should be better able to: Differentiate extrapulmonary neuroendocrine carcinoma (EP-NEC) from extrapulmonary neuroendocrine tumors (EP-NETs); Identify diagnostic and pathological approaches to improve the recognition and accurate classification of EP-NEC and EP-NET; Evaluate emerging clinical data on DLL3-targeting bispecific TCE agents in the treatment of EP-NEC and EP-NET; and Formulate evidence-based strategies to integrate DLL3-targeting bispecific TCE therapies into evolving treatment paradigms for EP-NEC and EP-NET.

Please visit answersincme.com/BJN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Rajesh Gandhi, MD. In this activity, an expert in infectious diseases discusses novel oral antiretroviral therapy (ART) for the management of human immunodeficiency virus (HIV). Upon completion of this activity, participants should be better able to: Recognize the rationale for novel oral ART regimens in the management of virologically suppressed HIV infection; Review the clinical impact of novel emerging oral ART regimens for patients with virologically suppressed HIV infection; and Formulate patient-centered strategies for optimizing the personalized management of oral ART for patients with virologically suppressed HIV infection.